Publications by authors named "Robyn Schecter"

Claim this Profile
C
Cost-effectiveness of fingolimod versus interferon-β1a for the treatment of pediatric-onset multiple sclerosis in Canada.
Hamid Reza Nakhaipour, Umakanth Vudumula, Vivek Khurana, Guillaume Sébire, Jean K Mah, Robyn Schecter

J Med Econ· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis and management of secondary-progressive multiple sclerosis: time for change.
Jiwon Oh, Katayoun Alikhani, Tania Bruno, Virginia Devonshire, Paul S Giacomini, Robyn Schecter

Neurodegener Dis Manag· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies.
Pierre Duquette, Michael Yeung, Soukaïna Mouallif, Hamid Reza Nakhaipour, Paola Haddad, Robyn Schecter

PLoS One· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches.
Francois Grand'Maison, Michael Yeung, Sarah A Morrow, Liesly Lee, Francois Emond, Robyn Schecter

Neural Regen Res· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment.
Francois Grand'Maison, Michael Yeung, Sarah A Morrow, Liesly Lee, Francois Emond, Robyn Schecter

Curr Med Res Opin· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canadian Experience with Fingolimod: Adherence to Treatment and Monitoring.
Yves Lapierre, Paul O'Connor, Virginia Devonshire, Mark S Freedman, Marcelo Kremenchutzky, Robyn Schecter

Can J Neurol Sci· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Balancing Early Aggression Against Risk of Progression in Multiple Sclerosis.
Pierre Duquette, Paul S Giacomini, Virender Bhan, Marika Hohol, Robyn Schecter

Can J Neurol Sci· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study.
Serge Gauthier, Alain Robillard, Sharon Cohen, Sandra Black, John Sampalis, Robyn Schecter

Curr Med Res Opin· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of rivastigmine on common symptomatology of Alzheimer's disease (EXPLORE).
Serge Gauthier, Angela Juby, William Dalziel, Bonita Réhel, Robyn Schecter

Curr Med Res Opin· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.
Serge Gauthier, Angela Juby, Lidia Morelli, Bonita Rehel, Robyn Schecter

Curr Med Res Opin· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis